Description
ORSERDU (elacestrant) tablets
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Get Access to ORSERDU(elacestrant) tablets In India
On request it available to patient and doctors. Medvitaz Pharma is equipped to facilitate the distribution of ORSERDU(elacestrant) tablets (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication “ORSERDU(elacestrant) tablets” or the generic version “elacestrant tablets” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.
REFERENCE
1. Orserdu (elacestrant) tablets, for oral use, prescribing information, Stemline Therapeutics, Inc, a Menarini Group company. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf. Accessed February 10, 2023.